Clinical trials: Leukemia, Lymphoid, Acute
Leukemia
Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be effective treatment for leukemia.
- Trial name
- NCT00643240
- Testing
- yttrium Y 90 anti-CD19 monoclonal antibody BU12, 111In-BU-12
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Diseases
Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics
Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor.
- Trial name
- BIOCART-HM (NCT04209829)
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoblastic Leukemia
A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
This is a national, multicenter, phase II clinical trial to evaluate the potential benefit of pre-transplant consolidation and post-transplant maintenance with navitoclax and venetoclax in patients with T-ALL, LBL and MPAL T/M in…
- Trial name
- ITALLI001 (NCT05054465)
- Testing
- Navitoclax, Venetoclax
- Where
- 6 sites in Israel
- Volunteers
- 48 people
- Sponsor
- Israeli Medical Association
Leukemia, Lymphoblastic (Acute)
Administration of Donor MultiTAA-Specific T Cells for ALL
This study uses special blood cells called multiple tumor-associated antigen (TAA)-specific T cells to treat patients with acute lymphoblastic leukemia (ALL) which has come back, or may come back, or has not gone away after…
- Trial name
- STELLA (NCT02475707)
- Testing
- MultiTAA-specific T cells
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Lymphoma, Neutropenia
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
RATIONALE: Colony-stimulating factors may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.
- Trial name
- NCT00004192
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Nebraska
B-cell Acute Lymphoblastic Leukemia
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Hypotheses: The Investigator hypothesizes that targeting ALL cells with 2 different modalities, ie liposomal vincristine sulfate as a microtubule inhibitor and blinatumomab as a BITE immuno-oncology therapy, will have at least…
- Trial name
- NCT04448834
- Testing
- Blinatumomab
- Where
- 3 sites in United States
- Sponsor
- Dorothy Sipkins, MD, PhD
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06195891
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Acute Lymphocytic Leukaemia
SAR3419 in Acute Lymphoblastic Leukemia
Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: Response duration Progression Free Survival Minimal residual disease Safety Pharmacokinetics
- Trial name
- MYRALL (NCT01440179)
- Testing
- SAR3419
- Where
- 11 sites in United States, France
- Volunteers
- 100 people
- Sponsor
- Sanofi
Leukemia, Myeloid, Acute, Leukemia, B-cell
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
This study is for patients who have a type of blood cancer that expresses the protein CD70, which includes acute myeloid leukemia (AML), T-cell leukemia or B-cell leukemia (and the leukemia has come back or has not gone away…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T-Cell
- Trial name
- CASEY (NCT06345027)
- Testing
- Treatment Arm A
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Baylor College of Medicine
T-ALL
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
The planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2).
- Trial name
- NCT06648889
- Testing
- Isatuximab
- Where
- 15 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Goethe University
Chronic Lung Disease, Chronic Obstructive Pulmonary Disease
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
This study aims to more accurately assess cardiac function, ventilation and exercise capacity in a non-invasive fashion, and to better characterize exercise intolerance in the setting of three populations of individuals with…
- Conditions
- Chronic Lung Disease, Chronic Obstructive Pulmonary Disease, Acute Lymphoblastic Leukemia, Heart Transplant
- Trial name
- FLASHLITE (NCT05025774)
- Testing
- Physical activity
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia
Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction
Recent advances in acute lymphoblastic leukemia treatment are based on a cytotoxic drug combination. Measurement of minimal residual disease in bone marrow samples at day 14 of treatment is the most powerful early predictive…
- Trial name
- PTX-II (NCT02451774)
- Testing
- Pentoxifylline Plus Chemotherapy
- Where
- Mexico
- Volunteers
- 44 people
- Sponsor
- Ramón Óscar González-Ramella, Ph.D
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
The purposee of this study is to determine the safety and dosing of Fenretinide when given continuously for 5 days, every 3 weeks, in pediatric patients with recurrent and/or resistant acute lymphoblastic leukemia (ALL), acute…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT01187810
- Testing
- Fenretinide, Cytarabine, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- South Plains Oncology Consortium
B-Cell Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia
Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
This is an open-label, multi-cohort, investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma…
- Trial name
- GI001-01 (NCT07862010)
- Testing
- GI001
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hematology department of the 920th hospital
Leukemia, Lymphoblastic
Evaluation of the Advantage in the Use of Enteral Nutrition in Children Treated for Acute Lymphoblastic Leukemia
This is a multicenter retrospective study (Reims and Nancy), with data collection over 12 years from 01/01/2010 to 12/31/2022 Patients included are children diagnosed with acute lymphoblastic leukemia between 2010 and 2021 in the…
- Trial name
- NCT06110182
- Testing
- enteral or parenteral nutritional support
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
This study is evaluating whether a weight-loss medication (PHEN/TOP) combined with healthy lifestyle counseling is safe, well tolerated, and can help reduce obesity in adolescents and young adults who are in remission from ALL…
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
- Trial name
- NCT07790913
- Testing
- Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed/Refractory Leukemia
Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)
This is a multicenter open-label phase II trial of trastuzumab in patients with HER2 positive B-ALL in relapse, or with refractory disease.
- Trial name
- NCT00724360
- Testing
- Herceptin (trastuzumab)
- Where
- 8 sites in France
- Volunteers
- 15 people
- Sponsor
- Nantes University Hospital
Diffuse Large Cell Lymphoma, Lymphoblastic Lymphoma
Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients
The purpose of this study is to define if flow cytometry has more sensitivity for detecting neoplastic cells in cerebrospinal fluid versus conventional cytology.
- Conditions
- Diffuse Large Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma
- Trial name
- CFM (NCT00949741)
- Where
- 12 sites in Italy
- Volunteers
- 175 people
- Sponsor
- Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) will be infused back to patients with refractory /relapsed B cell malignancies, including lymphoma and leukemia.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
- Trial name
- NCT03191773
- Testing
- Drugs and anti-CD19 CAR transduced T cells
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Acute Lymphocytic Leukemia
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
This is a phase I, open-label, single-arm study conducted in China to evaluate the safety, tolerability, PK, and determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) (if applicable) of JWCAR029 in…
- Trial name
- NCT05727683
- Testing
- CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.